To the top

Page Manager: Webmaster
Last update: 9/11/2012 3:13 PM

Tell a friend about this page
Print version

Opposing effects of immun… - University of Gothenburg, Sweden Till startsida
Sitemap
To content Read more about how we use cookies on gu.se

Opposing effects of immunotherapy in melanoma using multisubtype interferon-alpha - can tumor immune escape after immunotherapy accelerate disease progression?

Journal article
Authors Örjan Strannegård
Fredrik Bergh Thorén
Published in Oncoimmunology
Volume 5
Issue 3
Pages e1091147
ISSN 2162-402X
Publication year 2016
Published at Sahlgrenska Cancer Center
Institute of Biomedicine, Department of Infectious Medicine
Pages e1091147
Language en
Links dx.doi.org/10.1080/2162402x.2015.10...
Keywords Immunotherapy, Type I interferon, immunoediting, treatment outcome, antigen expression, prostate-cancer, clinical-trials, phase-iii, survival, vaccine, Oncology
Subject categories Clinical Medicine

Abstract

With checkpoint inhibitors, patients with advanced melanoma display durable responses suggesting cure of disease. However, the immune system has dual roles in cancer; while the immune system may eradicate a tumor, a subtotal elimination may selectively destroy immunogenic cells driving the proliferation of non-immunogenic tumors. Here, we performed a retrospective analysis of results obtained in a controlled trial of patients with melanoma treated with adjuvant, multisubtype interferon-. The survival curves displayed a late divergence for treated patients and controls resulting in substantially higher estimates of overall (OS) and relapse-free survival (RFS) rates among treated patients after 9 y of follow up. Interestingly, succumbing patients in the treatment group displayed reduced time between relapse and death, suggesting therapy-induced acceleration of disease progression. These findings suggest that effective immunotherapy that induces durable, curative responses in some patients, may potentially accelerate disease progression in others, highlighting the importance of developing advanced strategies to identify patients who are likely to benefit from immunotherapy.

Page Manager: Webmaster|Last update: 9/11/2012
Share:

The University of Gothenburg uses cookies to provide you with the best possible user experience. By continuing on this website, you approve of our use of cookies.  What are cookies?